Status:
RECRUITING
Hydroxycitrate: A Novel Therapy for Calcium Phosphate Urinary Stones
Lead Sponsor:
University of Texas Southwestern Medical Center
Conditions:
Calcium Phosphate Kidney Stones
Eligibility:
All Genders
21-99 years
Phase:
PHASE4
Brief Summary
This study tests whether hydroxycitrate, a molecule closely related to citrate, can reduce calcium phosphate stone recurrence.
Detailed Description
In this double-blind, placebo-controlled, randomized, crossover study, each participant will undergo 4 phases of study, with the order randomized by a blocked randomization scheme. The 4 phases will b...
Eligibility Criteria
Inclusion
- \- Calcium Phosphate stone formers
Exclusion
- History of recurrent urinary tract infections
- Chronic diarrhea
- Estimated Glomerular Filtration Rate (eGFR) \< 45 ml/min/1.73 m2
- History of primary hyperparathyroidism
- Hypokalemia
- Hyperkalemia
- Pregnancy
Key Trial Info
Start Date :
December 13 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 31 2028
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT06003348
Start Date
December 13 2023
End Date
August 31 2028
Last Update
April 6 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UT Southwestern Medical Center
Dallas, Texas, United States, 75390-8885